Volume 85 Issue 2 | Cancer Research | American Association for Cancer Research
Cancer Research | 85 | 2 | January 2025
Related Articles
2025 FDA-AACR Workshop: DPD Deficiency and Weighing Potential Harms
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Bob, Follicular Lymphoma Survivor
Bob, Follicular Lymphoma Survivor Bob took reasonable care of himself in his late 40’s. He swam every other day, played softball, played racquetball, and
Elinzanetant meets all endpoints in phase III trial for vasomotor symptoms caused by breast cancer treatments – The Cancer Letter
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused…
Cytokines in cancer
Kureshi and Dougan discuss the roles of cytokines in the tumor microenvironment. Although there is a sophisticated understanding of cytokine networks, therapeutically targeting cytokine pathways…
Going straight to the source in defense against infant RSV
Fred Hutch Cancer Center scientists developed an engineered antibody that may be able to target immune cells capable of producing a protective response against RSV.…
China’s NMPA clears country’s first mesenchymal stem cell therapy
China’s health regulator gave conditional approval to Platinum Life Excellence Biotech Co. Ltd.’s amimestrocel injection (hUC-MSC PLEB-001, Ruibosheng) as the nation’s first human umbilical cord-derived…
NCI Researchers Test Generalizability of Artificial Intelligence (AI) Model | CBIIT
The hallmark of a good AI model is its ability to work the same in different groups, settings, and situations. See how these NCI researchers…
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time oncology review, expediting access to this potential treatment.
Developing a tumor-specific vaccine for pancreatic cancer in the future
Karen Geboes, MD, PhD, UZ Gent – University Hospital Ghent, Ghent, Belgium, emphasizes the need for higher cure rates in patients with resectable pancreatic cancers.…
